LUNG CANCER

In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.

Findings from the FLAURA2 trial demonstrate that firstline treatment with osimertinib plus chemotherapy reduced the risk for central nervous system progression in patients with EGFR-positive non-small cell lung cancer.

Tina Cascone, MD, PhD, discusses the main findings from the phase 3 CheckMate-77T trial of a nivolumab-based regimen for the treatment of patients with stage IIA to IIIB non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.

Tarlatamab 10 mg showed responses in patients with previously treated small cell lung cancer, and no new safety signals were observed.

In a live virtual event, Yasir Y. Elamin, MD, discussed biomarker testing and management of non–small cell lung cancer (NSCLC) and a related patient case with participating physicians.

During a Targeted Oncology™ Clinical Case Forum event in partnership with the Nevada Oncology Society, Jonathan Riess, MD, MS, summarized the outcomes and impact of the PACIFIC and ADAURA trials in patients with nonmetastatic non–small cell lung cancer.

Neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab demonstrated improvements in event-free survival, pathologic complete response, and major pathologic response in non–small cell lung cancer.

Findings from a 3-year follow-up of the Checkmate-816 trial demonstrated promising results with nivolumab and platinum-based chemotherapy, including improvements in event-free survival.

In an interview with Targeted Oncology, Heather Wakelee, MD, discussed what community oncologists should know about the newly approved combination of pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment.

The FDA has approved pembrolizumab in the perioperative setting for resectable stage II, IIIA, or IIIB non–small cell lung cancer.

Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.

Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.

Sandip Patel, MD, discusses the durability of immunotherapy responses, updated survival data from clinical trials, and considerations for patients in the metastatic lung cancer setting.

A concise review of five-year updates from pivotal immunotherapy studies in lung cancer, highlighting the durability of responses and treatment options for high-risk disease

Expert perspectives on the significance and limitations of PD-L1 testing in non-small cell lung cancer and the importance of integrating genomic characterization for informed treatment choices.

Key insight into ongoing challenges and unmet needs in non-small cell lung cancer treatment, including specific patient populations and potential solutions through clinical trials.

A statistically significant overall survival benefit was observed with perioperative pembrolizumab in the phase 3 KEYNOTE-671 trial for patients with stage II, IIIA or IIIB non–small cell lung cancer.

Benny Weskler, MBA, MD, FACS, FACCP, discusses the introduction of immune checkpoint inhibitors in the neoadjuvant setting for patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the results of the phase 3 CodeBreaK 200 trial in patients with KRAS G12C-positive lung cancer. This is the second article based on this event.

A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.

In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.

Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.

Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.